Binds Virus Or Component Thereof Patents (Class 424/147.1)
  • Patent number: 11040098
    Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 22, 2021
    Assignee: FluGen, Inc.
    Inventors: Pamuk Bilsel, Yasuko Hatta
  • Patent number: 10745474
    Abstract: The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 18, 2020
    Assignees: Washington State University, The Board of Regents of the University of Texas Systems
    Inventors: Santanu Bose, Philippe Tessier
  • Patent number: 10654914
    Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: May 19, 2020
    Assignee: Novartis AG
    Inventors: Johanna Abend, Zorica Dragic, Adam Lloyd Feire, Mark Knapp, Steven Kovacs, Elisabetta Traggiai, Lichun Wang, Yongqiang Wang, Danqing Wu, Qilong Wu, Fangmin Xu
  • Patent number: 10640550
    Abstract: There has been a need for a neutralizing monoclonal antibody which is useful for antibody therapy effective against ebolavirus. The present invention provides a monoclonal antibody or an antigen-binding fragment thereof, which recognizes an internal fusion loop of ebolavirus GP and is capable of neutralizing the biological activity of ebolavirus.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: May 5, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Ayato Takada, Reiko Yoshida, Wakako Furuyama, Hiroko Miyamoto, Junki Maruyama, Shigeru Iida, Shinya Ogawa
  • Patent number: 10634676
    Abstract: Disclosed is a novel means of simultaneously detecting a human parvovirus B19 antigen and an IgM type anti-human parvovirus B19 antibody. The method of simultaneously detecting a human parvovirus B19 antigen and an IgM type anti-human parvovirus B19 antibody in a sample according to the present invention comprises bringing a sample into contact with (1) a 1st probe for detecting the parvovirus B19 antigen and (2) a 2nd probe for detecting the IgM type anti-parvovirus B19 antibody in the presence of a surfactant within the same reaction.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: April 28, 2020
    Assignee: FUJIREBIO INC.
    Inventors: Ran Gu, Atsushi Kaneko, Katsumi Aoyagi
  • Patent number: 10391165
    Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 27, 2019
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: William Jacobs, Jr., Pablo A. Gonzalez-Munoz, Betsy Herold, Christopher Petro
  • Patent number: 10030069
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 24, 2018
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • Patent number: 9957319
    Abstract: Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: May 1, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno
  • Patent number: 9649375
    Abstract: Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 16, 2017
    Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC.
    Inventors: Robert Francis Garry, Russell B. Wilson
  • Patent number: 9598481
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: March 21, 2017
    Assignee: Genetech, Inc.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swem
  • Patent number: 9403900
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: August 2, 2016
    Assignee: Crucell Holland B.V.
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
  • Patent number: 9383354
    Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: July 5, 2016
    Assignee: BIO-RAD LABORATORIES, INC.
    Inventors: William F. Link, Renato B. del Rosario, Randy Sweet, David L. King
  • Patent number: 9341391
    Abstract: This invention relates primarily to an electric heater based tankless water heater, though some aspects may also apply to a natural gas or other fuel based tankless water heater. In particular aspects relating to “smart” communication and coordination of the tankless water heater with other devices, which may be electrically powered or powered by other fuels, may also apply to non-electric flow through fluid heating systems. The subject tankless water heater invention incorporates several aspects relating to energy and construction efficiency which will be detailed further. These include both physical aspects, such as coatings, tubing and heater element design, and electrical aspects, such as power control for individual heater elements, which can make the tankless water heater more compact and more efficient in operation, with reduced instantaneous and long term load on electrical supply systems.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: May 17, 2016
    Assignees: Bollente Companies, Inc.
    Inventors: Micheal D. Stebbins, Steve Lurcott, Todd Kenneth Roper, Larry Martin, Brian Keith Roper
  • Patent number: 9340603
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that bind to hemagglutinin and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: May 17, 2016
    Assignee: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventor: Antonio Lanzavecchia
  • Patent number: 9321830
    Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: April 26, 2016
    Assignee: Trellis RSV Holdings, Inc.
    Inventors: Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
  • Patent number: 9284533
    Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: March 15, 2016
    Assignee: FLUGEN, INC.
    Inventors: Pamuk Bilsel, Yasuko Hatta
  • Patent number: 9221897
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: December 29, 2015
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 9217028
    Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 22, 2015
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 9200064
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: December 1, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus Hendrikus Jacobus Kwaks
  • Patent number: 9127049
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: September 8, 2015
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa MacAgno
  • Patent number: 9074013
    Abstract: The present application relates to a nucleic acid molecule having a nucleotide sequence encoding a bifunctional polypeptide comprising the DNA-binding domain of a protein belonging to the family of Methyl-CpG binding proteins (MBDs) and the Fc portion of an antibody. In addition, vectors and host cells which comprise said nucleic acid molecule and polypeptides which are encoded by said nucleic acid molecule as well as processes for producing said polypeptide are disclosed. Moreover, the present application provides an antibody specifically binding said polypeptide and compositions, in particular diagnostic compositions comprising the nucleic acid molecule(s), vector(s), host cell(s), polypeptide(s) or antibodie(s) of the present application. Furthermore, methods and uses employing the polypeptides of the present invention for detecting methylated DNA, in particular in tumorous tissue or tumor cells are provided.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: July 7, 2015
    Assignee: Sequenom, Inc.
    Inventor: Michael Rehli
  • Patent number: 9056902
    Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: June 16, 2015
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Christopher C. Broder, Katharine N. Bossart
  • Patent number: 9017668
    Abstract: Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: April 28, 2015
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • Patent number: 9011848
    Abstract: Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: April 21, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Mark Throsby
  • Patent number: 9005621
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: April 14, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • Publication number: 20150098948
    Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 9, 2015
    Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
  • Patent number: 8986686
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 24, 2015
    Assignee: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Patent number: 8975378
    Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: March 10, 2015
    Assignees: Osaka University, The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
  • Publication number: 20150056188
    Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 26, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Kenneth Simon, Thomas Cameron, Mia Rushe, Justin Caravella, George Campbell Kaynor
  • Publication number: 20150050271
    Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 19, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Kenneth Simon, Thomas Cameron, Deping Wang, Joseph Arndt, Mia Rushe, Justin Caravella, Eric Day
  • Publication number: 20150023979
    Abstract: The invention discloses a method for preparing Human Papilloma Virus protein E7 antigen (HPV E7 antigen) comprising the following steps: —providing a purified preparation of HPV protein E7; —phosphorylating the HPV protein E7 in the preparation; —purifying the phosphorylated E7 protein with an anion exchange chromatography, wherein the phosphorylated E7 protein is separated from the non-phosphorylated E7 protein by a step wherein the non-phosphorylated E7 protein stays bound to an anion exchanger during the anion exchange chromatography whereas the phosphorylated E7 protein is obtained in the eluate of the anion exchange chromatography, thereby—obtaining a purified preparation of a phosphorylated HPV protein E7 antigen. The invention further discloses antibodies specific to this antigen, a kit and method for using such antibodies in clinical diagnostics and methods for generation of such antibodies.
    Type: Application
    Filed: September 6, 2012
    Publication date: January 22, 2015
    Applicant: VALDOSPAN GMBH
    Inventor: Christian Kuhne
  • Patent number: 8911738
    Abstract: Provided are human binding molecules that specifically bind to a host cell protein and have virus neutralizing activity, nucleic acid molecules encoding such human binding molecules, compositions comprising the human binding molecules, and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: December 16, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Mark Throsby, Cornelis A. de Kruif
  • Publication number: 20140348851
    Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.
    Type: Application
    Filed: October 18, 2012
    Publication date: November 27, 2014
    Applicants: THE UNIVERSITY OF CHICAGO, EMORY UNIVERSITY
    Inventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
  • Patent number: 8894997
    Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: November 25, 2014
    Assignees: Vanderbilt University, Icahn School of Medicine at Mount Sinai
    Inventors: James E. Crowe, Christopher F. Basler
  • Patent number: 8871207
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: Humabs, LLC
    Inventor: Antonio Lanzavecchia
  • Publication number: 20140308282
    Abstract: Benzimidazoles of formula (I): wherein: A is 5- to 12-membered aryl or 5- to 12-membered heteroaryl, each of which is unsubstituted or substituted; Y is a single bond, —(CH2)p—, —X—, —CH2—X—, or —X—CH2—; X is —O—, —S—, —N(R2)—, >C?O, >S(?O), >S(?O)2, —O—C(?O)—, —C(?O)—O—, N(R2)—C(?O)—, or —C(?O)—N(R2)—; each L is independently a single bond, C1-3alkylene, C2-3alkenylene or C2-3alkynylene; R1 is C1-6alkyl, C2-6alkenyl or C2-6alkynyl, each of which is unsubstituted or substituted; each Z is independently —N(R2)2, —OR2, —SR2, —S(?O)R2, —S(?O)2R2; each R2 is independently hydrogen, C1-6alkyl, C2-6alkenyl or C2-6 alkynyl, wherein said alkyl, alkenyl and alkynyl groups are unsubstituted or substituted; m is 0, 1, 2, or 3; n is 1, 2, or 3; and p is 1, 2, or 3; and the pharmaceutically acceptable salt thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
    Type: Application
    Filed: November 12, 2012
    Publication date: October 16, 2014
    Applicant: re: Viral Ltd
    Inventors: Stuart Cockerill, Christopher Pilkington, James Lumley, Richard Angell, Neil Mathews
  • Patent number: 8858938
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: October 14, 2014
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation of the Advancement of Military Medicine, Inc.
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
  • Patent number: 8858946
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: October 14, 2014
    Assignees: The University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • Patent number: 8852594
    Abstract: The present invention provides anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: October 7, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventor: Ole Olsen
  • Patent number: 8852595
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: October 7, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • Patent number: 8852608
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 7, 2014
    Assignee: MedImmune, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
  • Patent number: 8834881
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 16, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • Patent number: 8828399
    Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 9, 2014
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Patent number: 8821876
    Abstract: Methods of identifying infectious disease infection prior to presentation of symptoms, assays for identifying genomic markers of infectious disease, and methods for diagnosing the underlying etiology of infectious disease.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: September 2, 2014
    Assignee: Duke University
    Inventors: Geoffrey S. Ginsburg, Joseph Lucas, Christopher W. Woods, Lawrence Carin, Aimee K. Zaas, Alfred Hero
  • Patent number: 8795667
    Abstract: The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the EV form of the smallpox virus. The invention relates to such compositions, especially to non-blood derived antibody compositions, such as chimeric or humanized antibodies, and to methods for their use in imparting passive immunity against smallpox infection to individuals at risk of smallpox virus infection or who exhibit smallpox.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: August 5, 2014
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Patent number: 8790872
    Abstract: A method of detecting the production of an analyte by cells in a sample, which method comprises: (i) providing an antibody capable of binding to said analyte and a first agent capable of enhancing detection of said analyte, wherein said antibody and said first agent are immobilized on the same support; (ii) contacting said antibody and said agent with a sample of cells; and (iii) detecting binding of said analyte to said antibody thereby detecting the production of an analyte by cells in a sample.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: July 29, 2014
    Assignee: Mabtech AB
    Inventors: Staffan Paulie, Sten Braesch-Andersen
  • Patent number: 8784819
    Abstract: Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: July 22, 2014
    Assignee: iBio Inc.
    Inventors: Vidadi Yusibov, Vadim Mett, Jessica Chichester, Lauren Goldschmidt
  • Patent number: 8784820
    Abstract: An antibody for activating plasminogen is provided. The antibody is produced from a hybridoma cell line deposited on Nov. 24, 2011 under accession number BCRC 960433 at Food Industry Research and Development Institute, 331 Shih-Pin Road, Hsinchu 300, Taiwan. The uses and producing method of the antibody, and an agent including the antibody used for treating stroke, myocardial infarction or syndromes cause by thrombus are also disclosed.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: July 22, 2014
    Inventors: Trai-Ming Yeh, Yung-Chun Chuang
  • Patent number: 8765132
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: July 1, 2014
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 8747856
    Abstract: The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition comprising a fully human binding fragment of an antibody for ocular topical administration for treatment or diagnosis of an ocular disease. In particular, the antibody neutralizes HSV1 and HSV2.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: June 10, 2014
    Assignee: Ribovax Biotechnologies S.A.
    Inventors: Claire Abadie, Jean-Marc Combette, Catherine Deloche, Robert Anthony Williamson